GO
Loading...

NPS Pharmaceuticals Inc

More

  • Feb 23- Rare disease drugmaker PTC Therapeutics Inc is exploring a potential sale amid takeover interest from several pharmaceutical companies, including Shire Plc and BioMarin Pharmaceutical Inc, according to people familiar with the matter. The stock of PTC Therapeutics, which has a market valuation of roughly $2 billion, rose as much as 25 percent to...

  • LONDON, Jan 26- Shire Plc shares gained more than 3 percent on Monday following news U.S. regulators had approved NPS Pharmaceuticals Inc's drug Natpara, validating Shire's decision to buy NPS for $5.2 billion.

  • Cramer: The biotech that doubled in value last year Friday, 16 Jan 2015 | 6:23 PM ET

    Jim Cramer has his eye on this amazing biotech that doubled in value last year, and thinks it could have plenty more upside.

  • Cramer’s top biotech has enormous value creation Thursday, 15 Jan 2015 | 6:42 PM ET

    This biotech just upped its guidance for 2015. Jim Cramer thinks it could have a lot more in the pipeline for profits.

  • Cramer Remix: Stay away from this stock Monday, 12 Jan 2015 | 7:11 PM ET
    Jim Cramer on Mad Money.

    "Mad Money" host Jim Cramer says this stock is too risky amid oil’s big decline.

  • Cramer: Ring the register on this hot biotech play Monday, 12 Jan 2015 | 6:58 PM ET

    This hot biotech play is up more than 40 percent, and Jim Cramer thinks it's time to rake in profits.

  • *Alcoa shares up after the bell. Oil prices extended their recent free-fall after Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. There's a lot of confusion and concern about the impact of oil prices, "said Tim Ghriskey, chief investment officer of Solaris Group in Bedford Hills, New York.

  • US stocks end lower with crude; Alcoa reports Monday, 12 Jan 2015 | 4:08 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks dropped Monday after a second weekly loss.

  • NEW YORK, Jan 12- U.S. stocks fell on Monday, led by a decline in energy shares as oil prices fell further while concern grew ahead of the start of corporate earnings season. Brent was down more than 5 percent to $47.44 and U.S. crude down 4.6 percent at $46.13, as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output.

  • Private equity, hedge fund stocks to outperform? Monday, 12 Jan 2015 | 10:04 AM ET
    Pedestrians walk outside an E*Trade Financial office in New York.

    Major investment banks and money center banks are not the best way to play Wall Street's success six years into a bull market, JMP Securities said.

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and weighed on equities, with both Brent and U.S. crude down about 4 percent as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the precipitous selloff in the...

  • *Foundation Medicine jumps; Roche to take majority stake. Oil prices continued their downward march and helped weaken futures, with Brent down 3.8 percent to $48.20 and U.S. crude down 3.7 percent to $46.59 as Goldman Sachs slashed its short-term price forecasts and Gulf producers showed no signs of curbing output. "During this cycle, since the beginning of the...

  • *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-week decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • Early movers: TIF, DLTR, CZR, MS, GM & more Monday, 12 Jan 2015 | 7:58 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures climb after two-week drop Monday, 12 Jan 2015 | 7:35 AM ET

    *Foundation Medicine jumps; Roche to take majority stake. NEW YORK, Jan 12- U.S. stock index futures rose on Monday, after a two-day decline pushed the S&P 500 back into negative territory for the year, as investors anticipated the start of the corporate earnings season. *Alcoa is scheduled to post quarterly earnings after the closing bell, with financials JPMorgan...

  • Goldman Sachs: Watch out for energy M&A in 2015 Monday, 12 Jan 2015 | 7:14 AM ET
    A derrick hand removes the the plastic caps off the threaded ends of pipe used in the drilling process in Knox County, Ohio.

    Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.

  • *Peugeot buoyed by broker upgrade. LONDON, Jan 12- European equities gained on Monday, led by rising healthcare stocks, after Shire agreed to buy NPS Pharmaceuticals for $5.2 billion and Roche also struck a deal. Chemicals shares also performed well after U.S. investment bank Citigroup upgraded several European chemicals companies, including BASF.

  • *European shares rise as Shire buys NPS Pharmaceuticals. The pan-European FTSEurofirst 300 index rose 0.3 percent to 1,352.67 points after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion. The euro zone's blue-chip Euro STOXX 50 index advanced 0.6 percent and Britain's FTSE 100 climbed 0.3 percent, helped by a 1.4 percent rise in Shire.

  • Rise in healthcare stocks lifts European equities Monday, 12 Jan 2015 | 3:20 AM ET

    LONDON, Jan 12- A rise in healthcare shares, following renewed signs of industry consolidation after Shire Plc agreed to buy NPS Pharmaceuticals for $5.2 billion, lifted European equities on Monday. "The Shire deal is likely to mean that there will be no fresh bid speculation coming through on Shire itself, although the ongoing consolidation within the industry...

  • Big deals, data kick off JPMorgan health conference Monday, 12 Jan 2015 | 1:04 AM ET

    The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.